Cantor Fitzgerald Reiterates “Overweight” Rating for Bicara Therapeutics (NASDAQ:BCAX)

Bicara Therapeutics (NASDAQ:BCAX)‘s stock had its “overweight” rating reaffirmed by Cantor Fitzgerald in a research report issued on Thursday,Benzinga reports. They currently have a $13.01 target price on the stock. Cantor Fitzgerald’s target price indicates a potential upside of 4.75% from the company’s current price.

Several other research analysts also recently issued reports on BCAX. Wedbush restated an “outperform” rating and set a $31.00 price objective on shares of Bicara Therapeutics in a research report on Wednesday, February 12th. HC Wainwright lifted their price objective on Bicara Therapeutics from $42.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, January 27th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Bicara Therapeutics has an average rating of “Buy” and a consensus price target of $36.50.

Bicara Therapeutics Price Performance

Shares of Bicara Therapeutics stock opened at $12.42 on Thursday. Bicara Therapeutics has a 1 year low of $11.10 and a 1 year high of $28.09. The stock’s 50 day moving average is $13.19.

Institutional Trading of Bicara Therapeutics

Several institutional investors have recently made changes to their positions in the stock. Vestal Point Capital LP grew its stake in shares of Bicara Therapeutics by 67.1% during the 4th quarter. Vestal Point Capital LP now owns 710,000 shares of the company’s stock valued at $12,368,000 after buying an additional 285,000 shares during the period. Wexford Capital LP purchased a new stake in shares of Bicara Therapeutics during the 4th quarter valued at $348,000. Red Tree Management LLC purchased a new stake in shares of Bicara Therapeutics during the 4th quarter valued at $55,230,000. Nuveen Asset Management LLC purchased a new stake in shares of Bicara Therapeutics during the 4th quarter valued at $436,000. Finally, Orbimed Advisors LLC grew its stake in shares of Bicara Therapeutics by 9.7% during the 4th quarter. Orbimed Advisors LLC now owns 298,301 shares of the company’s stock valued at $5,196,000 after buying an additional 26,391 shares during the period.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.